Applied BioCode Azione

Applied BioCode Conversione FCF

Il Tasso di Conversione FCF (FCF/EBITDA) di Applied BioCode (6598.TW) al 5 set 2026 è 117,03 %. L'anno precedente, Tasso di Conversione FCF (FCF/EBITDA) era 82,48 % — una variazione del 41,89% (superiore).

Conversione FCF

117,03 %

YoY

41,89%

Ultimo aggiornamento:

Tasso di Conversione FCF (FCF/EBITDA) di Applied BioCode ammonta a 2026 117,03 % . Tasso di Conversione FCF (FCF/EBITDA) di Applied BioCode ammontava a 2025 82,48 % . Diminuisce del 41,89% superiore rispetto all'anno precedente.

La storia di Applied BioCode Conversione FCF

  • 3 anni

  • 10 anni

  • 25 anni

  • Max

Conversione FCF
Date
Conversione FCF
1 gen 2018
113,80 TWD
1 gen 2019
120,75 TWD
1 gen 2020
168,79 TWD
1 gen 2021
101,72 TWD
1 gen 2022
-66,98 TWD
1 gen 2023
128,79 TWD
1 gen 2024
82,48 TWD
1 gen 2025
117,03 TWD
La storia di Applied BioCode Conversione FCF
ANNOConversione FCFYoY
117,03 %+41,89%
82,48 %-35,96%
128,79 %-292,30%
-66,98 %-165,84%
101,72 %-39,74%
168,79 %+39,79%
120,75 %+6,10%
113,80 %+17,11%
97,18 %-70,94%
334,44 %-70,13%
1119,73 %+491,95%
189,16 %
Access this data via the Eulerpool API

Applied BioCode Analisi delle Azioni

Cosa fa Applied BioCode? Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice. Applied BioCode è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Applied BioCode azioni

Tasso di Conversione FCF (FCF/EBITDA) di Applied BioCode è 117,03 % nel 2026.

Il Tasso di Conversione FCF (FCF/EBITDA) di Applied BioCode è passato da 82,48 % a 117,03 %, con una variazione del 41,89 %. Il valore è superiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Applied BioCode di Tasso di Conversione FCF (FCF/EBITDA) dal 2006, con valori annuali, grafici e analisi dettagliate.

La conversione FCF misura l'efficacia con cui l'EBITDA si converte in flusso di cassa libero. Una conversione più elevata indica un'efficiente allocazione di capitale e bassi costi di manutenzione.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Applied BioCode di Tasso di Conversione FCF (FCF/EBITDA) con i competitor del settore e la media industriale per valutare se è attraente.

Per valutare di Tasso di Conversione FCF (FCF/EBITDA), è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per Tasso di Conversione FCF (FCF/EBITDA).

Access this data via the Eulerpool API

Flussi di cassa — Applied BioCode

Tutte le Metriche Finanziarie — Applied BioCode